Circulating classical CD14++CD16- monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163

Oncology Reports

Volumn 34, Issue 3, 2015, Pages 1269-1278

  Lapuc, Izabela ^a   Bolkun, Lukasz ^a   Eljaszewicz, Andrzej ^a   Rusak, Malgorzata ^a   Luksza, Ewa ^a   Singh, Paulina ^a   Miklasz, Paula ^a   Piszcz, Jaroslaw ^a   Ptaszynska Kopczynska, Katarzyna ^a   Jasiewicz, Malgorzata ^a   Kaminski, Karol ^a   Dabrowska, Milena ^a   Bodzenta Lukaszyk, Anna ^a   Kloczko, Janusz ^a   Moniuszko, Marcin ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

CD163; Chronic lymphocytic leukemia; Monocytes; Prognostication; SCD163

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CD163 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IMMUNOLOGIC FACTOR; LEUKOCYTE ANTIGEN; VIDARABINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL MEMBRANE; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT DURATION; UPREGULATION; WATCHFUL WAITING; ANALOGS AND DERIVATIVES; BLOOD; CELL COUNT; CELL LINEAGE; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR EMBOLISM;

AGED; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL COUNT; CELL LINEAGE; CYCLOPHOSPHAMIDE; FEMALE; FLOW CYTOMETRY; GPI-LINKED PROTEINS; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MONOCYTES; NEOPLASTIC CELLS, CIRCULATING; RECEPTORS, CELL SURFACE; RECEPTORS, IGG; RITUXIMAB; VIDARABINE;

EID: 84937215606     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4088     Document Type: Article

References (56)

1. Chiorazzi N, Rai KR and Ferrarini M: Chronic lymphocytic leukemia. N Engl J Med 352: 804-815, 2005.
2. Z enz T, Mertens D, Küppers R, Döhner H and Stilgenbauer S: From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10: 37-50, 2010.
3. K orz C, Pscherer A, Benner A, Mertens D, Schaffner C, Leupolt E, Döhner H, Stilgenbauer S and Lichter P: Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood 99: 4554-4561, 2002.
4. Skrzeczyńska-Moncznik J, Bzowska M, Loseke S, Grage-Griebenow E, Zembala M and Pryjma J: Peripheral blood CD14high CD16+ monocytes are main producers of IL-10. Scand J Immunol 67: 152-159, 2008.
5. Z iegler-Heitbrock HW, Passlick B and Flieger D: The monoclonal antimonocyte antibody My4 stains B lymphocytes and two distinct monocyte subsets in human peripheral blood. Hybridoma 7: 521-527, 1988.
6. Z iegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, et al: Nomenclature of monocytes and dendritic cells in blood. Blood 116: e74-e80, 2010.
7. Moniuszko M, Bodzenta-Lukaszyk A, Kowal K, Lenczewska D and Dabrowska M: Enhanced frequencies of CD14++CD16+, but not CD14+CD16+, peripheral blood monocytes in severe asthmatic patients. Clin Immunol 130: 338-346, 2009.
8. Moniuszko M, Liyanage NP, Doster MN, Parks RW, Grubczak K, Lipinska D, McKinnon K, Brown C, Hirsch V, Vaccari M, et al: Glucocorticoid treatment at moderate doses of SIVmac251-infected rhesus macaques decreases the frequency of circulating CD14+CD16++ monocytes but does not alter the tissue virus reservoir. AIDS Res Hum Retroviruses 31: 115-126, 2015.
9. Eljaszewicz A, Wiese M, Helmin-Basa A, Jankowski M, Gackowska L, Kubiszewska I, Kaszewski W, Michalkiewicz J and Zegarski W: Collaborating with the enemy: Function of macrophages in the development of neoplastic disease. Mediators Inflamm 2013: 831387, 2013.
10. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M and Golay J: M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than M1 cells in vitro. J Immunol 182: 4415-4422, 2009.
11. Eljaszewicz A, Jankowski M, Gackowska L, Helmin-Basa A, Wiese M, Kubiszewska I, Kaszewski W, Michalkiewicz J and Zegarski W: Gastric cancer increase the percentage of intermediate (CD14++CD16+) and nonclassical (CD14+CD16+) monocytes. Centr Eur J Immunol 37: 355-361, 2012.
12. Heine GH, Ulrich C, Seibert E, Seiler S, Marell J, Reichart B, Krause M, Schlitt A, Köhler H and Girndt M: CD14++CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int 73: 622-629, 2008.
13. U lrich C, Heine GH, Gerhart MK, Köhler H and Girndt M: Proinflammatory CD14+CD16+ monocytes are associated with subclinical atherosclerosis in renal transplant patients. Am J Transplant 8: 103-110, 2008.
14. Foa R, Massaia M, Cardona S, Tos AG, Bianchi A, Attisano C, Guarini A, di Celle PF and Fierro MT: Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: A possible regulatory role of TNF in the progression of the disease. Blood 76: 393-400, 1990.
15. Gamberale R, Geffner J, Arrosagaray G, Scolnik M, Salamone G, Trevani A, Vermeulen M and Giordano M: Non-malignant leukocytes delay spontaneous B-CLL cell apoptosis. Leukemia 15: 1860-1867, 2001.
16. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M and Kipps TJ: Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96: 2655-2663, 2000.
17. Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, Reed JC, Zvaifler NJ and Kipps TJ: Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 106: 1012-1020, 2005.
18. Maffei R, Bulgarelli J, Fiorcari S, Bertoncelli L, Martinelli S, Guarnotta C, Castelli I, Deaglio S, Debbia G, De Biasi S, et al: The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica 98: 1115-1123, 2013.
19. Condeelis J and Pollard JW: Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263-266, 2006.
20. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, et al: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362: 875-885, 2010.
21. Etzerodt A and Moestrup SK: CD163 and inflammation: Biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal 18: 2352-2363, 2013.
22. Moniuszko M, Kowal K, Rusak M, Pietruczuk M, Dabrowska M and Bodzenta-Lukaszyk A: Monocyte CD163 and CD36 expression in human whole blood and isolated mononuclear cell samples: Influence of different anticoagulants. Clin Vaccine Immunol 13: 704-707, 2006.
23. Davis BH and Zarev PV: Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels. Cytometry B Clin Cytom 63: 16-22, 2005.
24. Møller HJ, Aerts H, Grønbaek H, Peterslund NA, Hyltoft Petersen P, Hornung N, Rejnmark L, Jabbarpour E and Moestrup SK: Soluble CD163: A marker molecule for monocyte/ macrophage activity in disease. Scand J Clin Lab Invest Suppl 237: 29-33, 2002.
25. Gui T, Shimokado A, Sun Y, Akasaka T and Muragaki Y: Diverse roles of macrophages in atherosclerosis: From inflammatory biology to biomarker discovery. Mediators Inflamm 2012: 693083, 2012.
26. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, et al; International Workshop on Chronic Lymphocytic Leukemia: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456, 2008.
27. Pardoll D: Does the immune system see tumors as foreign or self? Annu Rev Immunol 21: 807-839, 2003.
28. Mytar B, Wołoszyn M, Szatanek R, Baj-Krzyworzeka M, Siedlar M, Ruggiero I, Wieckiewicz J and Zembala M: Tumor cell-induced deactivation of human monocytes. J Leukoc Biol 74: 1094-1101, 2003.
29. Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174, 2009.
30. Ostrand-Rosenberg S and Sinha P: Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol 182: 4499-4506, 2009.
31. Seiffert M, Schulz A, Ohl S, Döhner H, Stilgenbauer S and Lichter P: Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood 116: 4223-4230, 2010.
32. Go NF, Castle BE, Barrett R, Kastelein R, Dang W, Mosmann TR, Moore KW and Howard M: Interleukin 10, a novel B cell stimulatory factor: Unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med 172: 1625-1631, 1990.
33. Rothe G, Gabriel H, Kovacs E, Klucken J, Stöhr J, Kindermann W and Schmitz G: Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler Thromb Vasc Biol 16: 1437-1447, 1996.
34. Ohri CM, Shikotra A, Green RH, Waller DA and Bradding P: Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 33: 118-126, 2009.
35. Wong KL, Tai JJ , Wong WC, Han H, Sem X, Yeap WH, Kourilsky P and Wong SC: Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 118: e16-e31, 2011.
36. Bieber K and Autenrieth SE: Insights how monocytes and dendritic cells contribute and regulate immune defense against microbial pathogens. Immunobiology 220: 215-226, 2015.
37. Z hou D, Huang C, Lin Z, Zhan S, Kong L, Fang C and Li J: Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways. Cell Signal 26: 192-197, 2014.
38. Beum PV, Kennedy AD and Taylor RP: Three new assays for rituximab based on its immunological activity or antigenic properties: Analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J Immunol Methods 289: 97-109, 2004.
39. Beum PV, Kennedy AD, Williams ME, Lindorfer MA and Taylor RP: The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 176: 2600-2609, 2006.
40. Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA and Taylor RP: Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol 181: 8120-8132, 2008.
41. Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W and Pasqualini R: A previously unrecognized protein-protein interaction between TWEAK and CD163: Potential biological implications. J Immunol 178: 8183-8194, 2007.
42. Moniuszko M, Kowal K, Jeznach M, Rusak M, Dabrowska M and Bodzenta-Lukaszyk A: Phenotypic correlations between monocytes and CD4+ T cells in allergic patients. Int Arch Allergy Immunol 161: 131-141, 2013.
43. Buechler C, Ritter M, Orsó E, Langmann T, Klucken J and Schmitz G: Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 67: 97-103, 2000.
44. Pioli PA, Goonan KE, Wardwell K and Guyre PM: TGF-beta regulation of human macrophage scavenger receptor CD163 is Smad3-dependent. J Leukoc Biol 76: 500-508, 2004.
45. Schaer DJ, Alayash AI and Buehler PW: Gating the radical hemoglobin to macrophages: The anti-inflammatory role of CD163, a scavenger receptor. Antioxid Redox Signal 9: 991-999, 2007.
46. Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO and Landis RC: Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: Antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 94: 119-126, 2004.
47. Hamann W, Flöter A, Schmutzler W and Zwadlo-Klarwasser G: Characterization of a novel anti-inflammatory factor produced by RM3/1 macrophages derived from glucocorticoid treated human monocytes. Inflamm Res 44: 535-540, 1995.
48. Shabo I, Stol O, Olsson H, Doré S and Svanvik J: Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer 123: 780-786, 2008.
49. Mansfield AS, Heikkila P, von Smitten K, Vakkila J and Leidenius M: The presence of sinusoidal CD163+ macrophages in lymph nodes is associated with favorable nodal status in patients with breast cancer. Virchows Arch 461: 639-646, 2012.
50. Goodale D, Phay C, Brown W, Gray-Statchuk L, Furlong P, Lock M, Chin-Yee I, Keeney M and Allan AL: Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer. Cytometry B Clin Cytom 76: 107-117, 2009.
51. Tiainen S, Tumelius R, Rilla K, Hämäläinen K, Tammi M, Tammi R, Kosma VM, Oikari S and Auvinen P: High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer. Histopathology 66: 873-883, 2015.
52. He KF, Zhang L, Huang CF, Ma SR, Wang YF, Wang WM, Zhao ZL, Liu B, Zhao YF, Zhang WF, et al: CD163+ tumorassociated macrophages correlated with poor prognosis and cancer stem cells in oral squamous cell carcinoma. BioMed Res Int 2014: 838632, 2014.
53. Chen L, Li Q, Zhou XD, Shi Y, Yang L, Xu SL, Chen C, Cui YH, Zhang X and Bian XW: Increased pro-angiogenic factors, infiltrating neutrophils and CD163+ macrophages in bronchoalveolar lavage fluid from lung cancer patients. Int Immunopharmacol 20: 74-80, 2014.
54. Lim R, Lappas M, Riley C, Borregaard N, Moller HJ, Ahmed N and Rice GE: Investigation of human cationic antimicrobial protein-18 (hCAP-18), lactoferrin and CD163 as potential biomarkers for ovarian cancer. J Ovarian Res 6: 5, 2013.
55. Wang J, Guo W, Du H, Yu H, Jiang W, Zhu T, Bai X and Wang P: Elevated soluble CD163 plasma levels are associated with disease severity in patients with hemorrhagic fever with renal syndrome. PLoS One 9: e112127, 2014.
56. Ye H, Wang LY, Zhao J and Wang K: Increased CD163 expression is associated with acute-on-chronic hepatitis B liver failure. World J Gastroenterol 19: 2818-2825, 2013.